7AY1 Stock Overview
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Actinium Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.26 |
| 52 Week High | US$8.67 |
| 52 Week Low | US$3.60 |
| Beta | 0.076 |
| 1 Month Change | -14.25% |
| 3 Month Change | 15.93% |
| 1 Year Change | -20.25% |
| 3 Year Change | -0.63% |
| 5 Year Change | 5.39% |
| Change since IPO | -95.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7AY1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | 0.8% | 1.2% |
| 1Y | -20.3% | -24.4% | 2.0% |
Return vs Industry: 7AY1 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 7AY1 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 7AY1 volatility | |
|---|---|
| 7AY1 Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7AY1's share price has been volatile over the past 3 months.
Volatility Over Time: 7AY1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 49 | Sandesh Seth | www.actiniumpharma.com |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA.
Actinium Pharmaceuticals, Inc. Fundamentals Summary
| 7AY1 fundamental statistics | |
|---|---|
| Market cap | €191.27m |
| Earnings (TTM) | -€43.42m |
| Revenue (TTM) | €75.72k |
2,526x
P/S Ratio-4.4x
P/E RatioIs 7AY1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7AY1 income statement (TTM) | |
|---|---|
| Revenue | US$81.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$81.00k |
| Other Expenses | US$46.53m |
| Earnings | -US$46.45m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -57,346.91% |
| Debt/Equity Ratio | 0% |
How did 7AY1 perform over the long term?
See historical performance and comparison